In clinical trials, endpoints are used to measure the effects of a therapy. While a true clinical endpoint directly measures how a patient feels, functions, or survives, researchers often use surrogate endpoints as a substitute. For PharmD students, the ability to critically evaluate clinical literature requires a deep understanding of the validity, application, and limitations of surrogate endpoints, especially in fields like oncology where they are commonly used.
1. A surrogate endpoint in a clinical trial is best defined as:
- A direct measure of how a patient feels, functions, or survives
- A laboratory measure or physical sign used as a substitute for a clinically meaningful endpoint
- An endpoint that is only used in Phase 1 trials
- A measure of the cost-effectiveness of the therapy
Answer: A laboratory measure or physical sign used as a substitute for a clinically meaningful endpoint
2. Which of the following is considered the “gold standard” clinical endpoint in most oncology clinical trials?
- Tumor response rate
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- Biomarker normalization
Answer: Overall Survival (OS)
3. A primary advantage of using a surrogate endpoint in a clinical trial is that it can:
- Always perfectly predict the effect on the true clinical endpoint
- Allow for a trial to be completed more quickly and with fewer patients
- Eliminate the placebo effect
- Provide a direct measure of patient quality of life
Answer: Allow for a trial to be completed more quickly and with fewer patients
4. In a hypertension trial, a change in blood pressure is often used as a surrogate endpoint for the true clinical endpoint of:
- Stroke or myocardial infarction
- Serum creatinine
- Patient-reported dizziness
- The cost of the medication
Answer: Stroke or myocardial infarction
5. Progression-Free Survival (PFS) in an oncology trial is defined as the length of time that a patient:
- Lives after starting treatment, regardless of disease status
- Lives with the disease without it getting worse
- Experiences a complete disappearance of the tumor
- Remains on the study drug without any side effects
Answer: Lives with the disease without it getting worse
6. A major limitation or “divorce” discussed in oncology literature is when a drug improves a surrogate like PFS but fails to improve:
- The tumor response rate
- The drug’s palatability
- Overall Survival (OS)
- The patient’s white blood cell count
Answer: Overall Survival (OS)
7. For a surrogate endpoint to be considered valid, it must:
- Be easy and inexpensive to measure
- Be on the causal pathway of the disease
- Accurately predict the effect on the clinical endpoint
- Be a novel biomarker
Answer: Accurately predict the effect on the clinical endpoint
8. Which of the following is a direct measure of clinical benefit, and therefore NOT a surrogate endpoint?
- Lowering LDL cholesterol
- Reducing viral load in HIV
- Preventing death from cardiovascular disease
- Shrinking a tumor
Answer: Preventing death from cardiovascular disease
9. The use of surrogate endpoints can lead to what potential regulatory outcome?
- A delay in the drug approval process
- Accelerated approval of a drug by the FDA
- A requirement for longer and larger clinical trials
- The immediate generic availability of the drug
Answer: Accelerated approval of a drug by the FDA
10. “Response Rate” in an oncology trial, a common surrogate endpoint, typically measures the proportion of patients whose:
- Tumors shrink by a certain amount
- Quality of life improves
- Survival is extended by five years
- White blood cell count returns to normal
Answer: Tumors shrink by a certain amount
11. A key challenge when interpreting a trial that uses only a surrogate endpoint is the:
- Certainty that the results translate to meaningful patient benefit
- Uncertainty about whether the observed effect on the surrogate will lead to a real clinical benefit
- Simplicity of the statistical analysis
- Fact that these trials are always double-blind
Answer: Uncertainty about whether the observed effect on the surrogate will lead to a real clinical benefit
12. In diabetes trials, a reduction in HbA1c is a surrogate endpoint for:
- The prevention of long-term microvascular complications
- The immediate cure of diabetes
- The cost of insulin
- Patient satisfaction with treatment
Answer: The prevention of long-term microvascular complications
13. Why might a drug improve Progression-Free Survival (PFS) but not Overall Survival (OS)?
- The drug has significant toxicity that counteracts the benefit of delaying progression
- Patients receive effective subsequent therapies after progressing on the study drug
- The delay in progression is not long enough to impact survival
- All of the above
Answer: All of the above
14. When critically appraising a clinical trial, a pharmacist should always question the ________ of the surrogate endpoint used.
- color
- name
- validity
- cost
Answer: validity
15. The “applicability to clinical practice” of a trial that relies on a surrogate endpoint depends heavily on:
- The strength of the association between the surrogate and the true clinical endpoint
- The number of patients enrolled in the trial
- The reputation of the journal in which it was published
- The cost of the study drug
Answer: The strength of the association between the surrogate and the true clinical endpoint
16. A drug could lower a patient’s cholesterol (surrogate endpoint) but fail to reduce heart attacks (clinical endpoint) if the drug:
- Has an off-target effect that increases cardiovascular risk, like raising blood pressure
- Is too inexpensive
- Is too effective at lowering cholesterol
- Has no side effects
Answer: Has an off-target effect that increases cardiovascular risk, like raising blood pressure
17. The evaluation of surrogate endpoints is a key topic in courses on:
- Clinical trial evaluation and evidence-based practice
- Sterile compounding
- Pharmacy law
- The history of pharmacy
Answer: Clinical trial evaluation and evidence-based practice
18. In HIV/AIDS treatment, a reduction in viral load is a well-accepted surrogate endpoint for:
- Curing the HIV infection
- Delaying the progression to AIDS and improving survival
- The cost of antiretroviral therapy
- The patient’s adherence to the medication
Answer: Delaying the progression to AIDS and improving survival
19. What is a primary reason for the “divorce” between response rate and overall survival in oncology?
- Tumor shrinkage does not always translate into a longer life, especially if it is not durable or if the tumor becomes resistant
- Response rate is a direct measure of survival
- All tumors that shrink will eventually be cured
- Response rate is more difficult to measure than survival
Answer: Tumor shrinkage does not always translate into a longer life, especially if it is not durable or if the tumor becomes resistant
20. A pharmacist explaining trial results to a physician should be careful to:
- Equate a change in a surrogate endpoint with a proven clinical benefit
- Differentiate between a statistically significant change in a surrogate endpoint and a proven clinical benefit
- Ignore the endpoint that was used in the trial
- Focus only on the p-value of the primary endpoint
Answer: Differentiate between a statistically significant change in a surrogate endpoint and a proven clinical benefit
21. Which of the following is a true clinical endpoint?
- Bone mineral density
- Prevention of a hip fracture
- Serum lipid levels
- Blood glucose levels
Answer: Prevention of a hip fracture
22. The main appeal of using PFS as a primary endpoint in an oncology trial is that:
- It occurs earlier than death, allowing for faster trial results
- It is a direct measure of patient quality of life
- It is less expensive to measure than overall survival
- It is not affected by subsequent lines of therapy
Answer: It occurs earlier than death, allowing for faster trial results
23. The concept of “clinical outcomes” is a fundamental part of:
- Evidence-based medicine
- Pharmaceutical calculations
- Drug compounding
- Pharmacy informatics
Answer: Evidence-based medicine
24. A drug receives accelerated approval based on a surrogate endpoint. What is typically required by the FDA post-approval?
- A confirmatory trial to verify the drug’s effect on a true clinical endpoint
- No further studies are needed
- A trial comparing the drug to placebo in healthy volunteers
- A price reduction for the medication
Answer: A confirmatory trial to verify the drug’s effect on a true clinical endpoint
25. A key question a pharmacist should ask when evaluating a trial based on a surrogate is:
- How well-established is the link between this surrogate and a meaningful patient outcome?
- Is the surrogate endpoint easy to pronounce?
- Was the trial sponsored by a large pharmaceutical company?
- How many authors are on the paper?
Answer: How well-established is the link between this surrogate and a meaningful patient outcome?
26. A patient-reported outcome (PRO) that measures symptoms or quality of life is considered a:
- Surrogate endpoint
- Clinical endpoint
- Biomarker
- Pharmacokinetic parameter
Answer: Clinical endpoint
27. In some cases, a significant improvement in PFS can be considered:
- A clinically meaningful benefit on its own, even if OS is not improved
- An irrelevant finding in all circumstances
- A sign that the drug is not effective
- A reason to stop the clinical trial early for futility
Answer: A clinically meaningful benefit on its own, even if OS is not improved
28. The use of surrogate endpoints is most common in trials for:
- Chronic diseases where the true clinical endpoint may take years to occur
- Acute conditions that resolve quickly
- Healthy volunteers
- Non-pharmacological interventions
Answer: Chronic diseases where the true clinical endpoint may take years to occur
29. The main focus of the reading “Irreconcilable Differences” is the frequent disconnect between:
- Response rates, PFS, and Overall Survival
- Phase 1 and Phase 2 clinical trials
- The cost of a drug and its efficacy
- Pharmacists and physicians
Answer: Response rates, PFS, and Overall Survival
30. When a new drug is approved based on a surrogate endpoint, pharmacists play a crucial role in:
- Monitoring for the drug’s real-world effect on clinical outcomes
- Recommending the drug for all patients regardless of indication
- Ignoring the post-marketing surveillance data
- Assuming the drug is curative for the disease
Answer: Monitoring for the drug’s real-world effect on clinical outcomes
31. Which of these is a surrogate endpoint?
- Stroke
- Heart attack
- CD4 cell count in HIV
- Death
Answer: CD4 cell count in HIV
32. A potential bias when measuring Progression-Free Survival is that:
- It is an objective measure with no room for interpretation
- The timing and frequency of tumor assessments can influence the results
- It can only be measured at the end of a patient’s life
- It is not affected by imaging technology
Answer: The timing and frequency of tumor assessments can influence the results
33. An ideal surrogate endpoint should capture the ________ effect of a treatment on the clinical endpoint.
- opposite
- net
- partial
- unrelated
Answer: net
34. The FDA’s acceptance of a surrogate endpoint for a specific disease is based on:
- The biological plausibility of the relationship
- Epidemiological evidence
- Evidence from clinical trials
- All of the above
Answer: All of the above
35. A pharmacist reading a clinical trial abstract should first identify:
- The primary endpoint of the study and whether it is a clinical or surrogate endpoint
- The names of all the study investigators
- The statistical software that was used for the analysis
- The location where the study was conducted
Answer: The primary endpoint of the study and whether it is a clinical or surrogate endpoint
36. Overall Survival (OS) is considered a robust clinical endpoint because it is:
- Easy to measure and not subject to interpretation bias
- A subjective measure reported by the patient
- The earliest endpoint to occur in a trial
- The best measure of tumor shrinkage
Answer: Easy to measure and not subject to interpretation bias
37. When counseling a patient about a new drug approved based on a surrogate endpoint, it is important to convey:
- That the drug is guaranteed to make them live longer
- That the drug has been shown to improve a marker related to their disease, and studies on long-term benefit are ongoing
- That the drug has no known side effects
- That the drug is still considered experimental and should not be taken
Answer: That the drug has been shown to improve a marker related to their disease, and studies on long-term benefit are ongoing
38. The “Prentice criteria” are a set of statistical conditions used for what purpose?
- To validate a surrogate endpoint
- To calculate a p-value
- To randomize patients in a clinical trial
- To determine the cost of a drug
Answer: To validate a surrogate endpoint
39. A focus on surrogate endpoints is a key component of understanding:
- Drug literature evaluation
- Non-sterile compounding
- Pharmacy calculations
- Health informatics
Answer: Drug literature evaluation
40. If a trial shows a drug improves a surrogate endpoint but worsens quality of life, the drug’s overall value is:
- Clearly established
- Questionable
- Not relevant to the pharmacist
- Guaranteed to be high
Answer: Questionable
41. The use of surrogate endpoints is driven by a need for more ________ drug development and approval.
- expensive
- lengthy
- efficient
- complicated
Answer: efficient
42. Which of the following best describes the relationship between a surrogate endpoint and a clinical outcome?
- The surrogate is intended to be a predictor of the clinical outcome
- The clinical outcome is a predictor of the surrogate endpoint
- The two are completely independent of each other
- The surrogate endpoint is always a more reliable measure
Answer: The surrogate is intended to be a predictor of the clinical outcome
43. A pharmacist must be cautious when a new drug’s marketing focuses exclusively on its effect on a(n):
- Validated clinical endpoint
- Unvalidated surrogate endpoint
- Overall survival
- Quality of life measure
Answer: Unvalidated surrogate endpoint
44. In a trial for osteoporosis, bone mineral density (BMD) is a common surrogate endpoint for what?
- The clinical endpoint of fractures
- The cost of calcium supplements
- Patient-reported pain
- The patient’s height
Answer: The clinical endpoint of fractures
45. The “divorce” between surrogate and clinical endpoints highlights the importance of:
- Relying solely on surrogate endpoints for all clinical decisions
- Critical appraisal of the evidence and not over-interpreting surrogate data
- Disregarding all clinical trials that use surrogate endpoints
- Trusting all conclusions presented in a research paper
Answer: Critical appraisal of the evidence and not over-interpreting surrogate data
46. A lecture on surrogate endpoints in oncology would likely emphasize the difference between:
- PFS and OS
- Phase 1 and Phase 4 trials
- Intravenous and oral chemotherapy
- Benign and malignant tumors
Answer: PFS and OS
47. The primary reason a trial might choose PFS over OS as its primary endpoint is:
- OS is a less important outcome to patients
- PFS events (progression or death) occur more frequently and earlier than death alone
- PFS is a more objective measure than OS
- The FDA no longer accepts OS as a valid endpoint
Answer: PFS events (progression or death) occur more frequently and earlier than death alone
48. Evaluating the “applicability to clinical practice” requires a pharmacist to consider if the trial’s endpoints are:
- Statistically significant
- Relevant and meaningful to their own patient population
- Easy to measure in the lab
- Novel and previously unpublished
Answer: Relevant and meaningful to their own patient population
49. An understanding of surrogate endpoints is most critical when evaluating trials for what type of drugs?
- Drugs with a long history of established clinical benefit
- Drugs seeking accelerated approval based on early data
- Over-the-counter medications
- Generic drugs seeking approval based on bioequivalence
Answer: Drugs seeking accelerated approval based on early data
50. The ultimate goal when using a surrogate endpoint is that an improvement in the surrogate will:
- Lead to a tangible, beneficial effect on how a patient feels, functions, or survives
- Increase the cost of the drug
- Make the drug more difficult to administer
- Have no correlation with the patient’s actual health status
Answer: Lead to a tangible, beneficial effect on how a patient feels, functions, or survives
